EDWARDS LIFESCIENCES CORP (EWL.DE) Stock Price, Forecast & Analysis
Europe - FRA:EWL - US28176E1082 - Common Stock
EWL.DE Key Statistics, Chart & Performance
The current stock price of EWL.DE is 73.91 EUR. In the past month the price increased by 18.2%. In the past year, price increased by 16.3%.
EWL.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 2M6.DE | MEDTRONIC PLC | 17.33 | 105.58B | ||
| SHL.DE | SIEMENS HEALTHINEERS AG | 21.99 | 47.13B | ||
| 1SHL.MI | SIEMENS HEALTHINEERS AG | 18.38 | 49.34B | ||
| PHI1.DE | KONINKLIJKE PHILIPS NV | 17.22 | 23.87B | ||
| PHIA.AS | KONINKLIJKE PHILIPS NV | 16.9 | 23.44B | ||
| BIM.PA | BIOMERIEUX | 27.63 | 12.62B | ||
| AFX.DE | CARL ZEISS MEDITEC AG - BR | 24.26 | 3.71B | ||
| DIA.MI | DIASORIN SPA | 16.96 | 3.29B | ||
| DRW3.DE | DRAEGERWERK AG - PREF | 10.6 | 1.28B | ||
| DRW8.DE | DRAEGERWERK AG | 9.49 | 1.15B | ||
| EUZ.DE | ECKERT & ZIEGLER SE | 27.31 | 1.02B | ||
| ELN.MI | EL.EN. SPA | 17.63 | 905.40M |
Related stock screener links
About EWL.DE
Company Profile
Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. The company is headquartered in Irvine, California and currently employs 15,800 full-time employees. The company went IPO on 2000-03-27. The firm partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. The company provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. The company is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
Company Info
EDWARDS LIFESCIENCES CORP
One Edwards Way
Irvine CALIFORNIA US
Employees: 15800
Phone: 19492502500
EDWARDS LIFESCIENCES CORP / EWL.DE FAQ
Can you describe the business of EDWARDS LIFESCIENCES CORP?
Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. The company is headquartered in Irvine, California and currently employs 15,800 full-time employees. The company went IPO on 2000-03-27. The firm partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. The company provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. The company is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
Can you provide the latest stock price for EDWARDS LIFESCIENCES CORP?
The current stock price of EWL.DE is 73.91 EUR. The price decreased by -0.7% in the last trading session.
Does EWL stock pay dividends?
EWL.DE does not pay a dividend.
What is the ChartMill technical and fundamental rating of EWL stock?
EWL.DE has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What sector and industry does EDWARDS LIFESCIENCES CORP belong to?
EDWARDS LIFESCIENCES CORP (EWL.DE) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
What is the market capitalization of EWL stock?
EDWARDS LIFESCIENCES CORP (EWL.DE) has a market capitalization of 43.39B EUR. This makes EWL.DE a Large Cap stock.
Can you provide the ownership details for EWL stock?
You can find the ownership structure of EDWARDS LIFESCIENCES CORP (EWL.DE) on the Ownership tab.
EWL.DE Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to EWL.DE. When comparing the yearly performance of all stocks, EWL.DE is one of the better performing stocks in the market, outperforming 78.1% of all stocks.
EWL.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to EWL.DE. EWL.DE has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
EWL.DE Financial Highlights
Over the last trailing twelve months EWL.DE reported a non-GAAP Earnings per Share(EPS) of 2.21. The EPS decreased by -3.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 23.25% | ||
| ROA | 10.31% | ||
| ROE | 13.4% | ||
| Debt/Equity | 0.06 |
EWL.DE Forecast & Estimates
43 analysts have analysed EWL.DE and the average price target is 77.32 EUR. This implies a price increase of 4.61% is expected in the next year compared to the current price of 73.91.
For the next year, analysts expect an EPS growth of 0.42% and a revenue growth 4.33% for EWL.DE